Tags » Hemophilia A

Roche's drug Hemlibra was approved by the FDA

Hemlibra was approved by the FDA as the first new drug to treat hemophilia A in the body in the past 20 years.

Sandra Horning, Roche’s chief medical officer and head of global product development, said: ” the approval of Hemlibra is of great significance for hemophilia A patients who have factor VIII inhibitors in the body.  54 more words

Latest News

Hemophilia A market key players, size, types, market growth and 2017-2022 forecasts

Hemophilia A Market

Latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A – Pipeline Review, H2 2017, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape. 741 more words

Consumer Goods

FDA approves new treatment Hemlibra (emicizumab-kxwh) to prevent bleeding in certain patients with hemophilia A

FDA approves new treatment to prevent bleeding in certain patients with hemophilia A

The U.S. Food and Drug Administration today approved Hemlibra (emicizumab-kxwh) to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors. 644 more words

0rphan Drug Status

BioMarin to Begin Phase 3 Gene Therapy Trials for Hemophilia A

BioMarin announced the results from their ongoing Phase 1/2 gene therapy studies evaluating  BMN 270 for patients with hemophilia A. Based on encouraging data, Phase 3 studies are being planned to start later this year. 433 more words


EU Grants €5.6 Million to Consortium Developing Sernova’s Cell Pouch Therapy for Hemophilia A Patients

The European Commission will award the Brussels-based HemAcure Consortium €5.6 million in next-stage funding of a therapy called Cell Pouch —  developed in collaboration with Canada’s  291 more words


Phase 3 Trials Evaluating Further Potential of 2 Treatments for Hemophilia A

Interim results of Phase 3 clinical studies investigating two major challenges in hemophilia — the development of inhibitors (antibodies to the drug used to treat bleeding episodes) and the need for repeated venous injection of blood clotting protein Factor VIII (FVIII) — were recently released. 543 more words


FDA Accepts Bioverativ’s Investigational New Drug Application for BIVV001 to Treat Hemophilia A

The U.S. Food and Drug Administration (FDA) has accepted Bioverativ’s investigational new drug application (IND) for BIVV001, an investigational Factor VIII therapy designed to extend protection from bleeds in  302 more words